Skip to main content
Delfa

← All assets

Trontinemab

5 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

5

Ongoing

4

Recruiting

2

Completed

1

Sites

289

Countries

19

Endpoints

60

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 60 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
1
Phase 1/2
1
Phase 3
3

Trials by status

Not yet recruiting
1
Recruiting
2
Active, not recruiting
1
Completed
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Safety / tolerability / PK
24
Global cognition
10
Other (unclassified)
9
Amyloid biomarkers
8
Fluid / digital biomarkers
3
Function / daily living
2
Tau biomarkers
2
Neurodegeneration biomarkers
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 14 of 60 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

4

ADAS-CogCognition

2

ADCS-Activities of Daily Living (ADCS-ADL)Function

2

Mini-Mental State Examination (MMSE)Cognition

2

Phosphorylated tau 181 (p-tau181)Amyloid

2

Phosphorylated tau 217 (p-tau217)Neurodeg.

2

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

5 of 5

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
TRONTIER 2A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Trontinemab

Alzheimer’s disease

MCI due to ADPh 3Recruiting150Jun 2028-
TRONTIER 1A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Trontinemab

Alzheimer’s disease

MCI due to ADPh 3Recruiting143Jun 2028-
NCT04639050Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

Trontinemab

Alzheimer’s disease

MCI due to AD / prodromal AD / mild-to-moderate AD / moderate AD dementiaPh 1/2Active, not recruiting41Jul 2027-
NCT04023994A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

Trontinemab

Alzheimer’s disease

Age 18-40Ph 1Completed1Jul 20201results
PrevenTRONA Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

Trontinemab

Alzheimer’s disease

Age 55-80Ph 3Not yet recruiting0--

Showing 1-5 of 5 trials